Literature DB >> 18783467

IL-12 p80-dependent macrophage recruitment primes the host for increased survival following a lethal respiratory viral infection.

Sean Gunsten1, Cassandra L Mikols, Mitchell H Grayson, Reto A Schwendener, Eugene Agapov, Rose M Tidwell, Carolyn L Cannon, Steven L Brody, Michael J Walter.   

Abstract

A protective immune response to a respiratory viral infection requires a series of coordinated cellular and molecular responses. We have previously demonstrated that increased expression of airway epithelial cell interleukin (IL)-12 p80, a macrophage chemoattractant, is associated with human respiratory viral infection and mediates post-viral mortality in the mouse. To better understand the role of IL-12 p80-dependent macrophage chemotaxis in mediating viral immunity, we generated a transgenic mouse strain utilizing a promoter to drive IL-12 p40 gene expression in the airway epithelium. This transgenic strain secreted biologically active IL-12 p80 in a lung-specific manner, and demonstrated a selective increase in the number of resident, unactivated airway macrophages at baseline. Following infection with a sublethal dose of mouse parainfluenza virus type 1 (Sendai virus), the transgenic mice demonstrated an earlier peak and decline in the number of airway inflammatory cells. The transgenic mice were resistant to a lethal dose of virus and this viral resistance was dependent on the increased number of airway macrophages at baseline as partial depletion prior to infection abrogated this phenotype. The survival advantage in the transgenic mice was independent of viral load but was associated with a more rapid decline in the number of airway inflammatory cells and concentrations of multiple chemokines including the CC chemokine ligand 2 (CCL2)/JE, CCL3/macrophage inflammatory protein (MIP)-1alpha, CCL4/MIP-1beta, and CCL5/RANTES. Collectively, these results suggest that IL-12 p80-driven increases in the number of resident airway macrophages prime the host for a protective immune response that can confer increased survival following a lethal respiratory viral infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18783467      PMCID: PMC2673362          DOI: 10.1111/j.1365-2567.2008.02923.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  48 in total

1.  Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia.

Authors:  Sylvia Knapp; Jaklien C Leemans; Sandrine Florquin; Judith Branger; Nico A Maris; Jennie Pater; Nico van Rooijen; Tom van der Poll
Journal:  Am J Respir Crit Care Med       Date:  2002-09-25       Impact factor: 21.405

2.  Roles of macrophages in measles virus infection of genetically modified mice.

Authors:  B Roscic-Mrkic; R A Schwendener; B Odermatt; A Zuniga; J Pavlovic; M A Billeter; R Cattaneo
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Disruption of neutrophil migration in a conditional transgenic model: evidence for CXCR2 desensitization in vivo.

Authors:  M T Wiekowski; S C Chen; P Zalamea; B P Wilburn; D J Kinsley; W W Sharif; K K Jensen; J A Hedrick; D Manfra; S A Lira
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

4.  Inflammatory skin disease in K14/p40 transgenic mice: evidence for interleukin-12-like activities of p40.

Authors:  T Kopp; J D Kieffer; A Rot; S Strommer; G Stingl; T S Kupper
Journal:  J Invest Dermatol       Date:  2001-09       Impact factor: 8.551

5.  Induction of nitric-oxide synthase and activation of NF-kappaB by interleukin-12 p40 in microglial cells.

Authors:  K Pahan; F G Sheikh; X Liu; S Hilger; M McKinney; T M Petro
Journal:  J Biol Chem       Date:  2000-12-07       Impact factor: 5.157

6.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.

Authors:  B Oppmann; R Lesley; B Blom; J C Timans; Y Xu; B Hunte; F Vega; N Yu; J Wang; K Singh; F Zonin; E Vaisberg; T Churakova; M Liu; D Gorman; J Wagner; S Zurawski; Y Liu; J S Abrams; K W Moore; D Rennick; R de Waal-Malefyt; C Hannum; J F Bazan; R A Kastelein
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

7.  Viral induction of a chronic asthma phenotype and genetic segregation from the acute response.

Authors:  Michael J Walter; Jeffrey D Morton; Naohiro Kajiwara; Eugene Agapov; Michael J Holtzman
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

8.  Induction of tumor necrosis factor-alpha (TNF-alpha) by interleukin-12 p40 monomer and homodimer in microglia and macrophages.

Authors:  Malabendu Jana; Subhajit Dasgupta; Ramendra N Saha; Xiaojuan Liu; Kalipada Pahan
Journal:  J Neurochem       Date:  2003-07       Impact factor: 5.372

Review 9.  Interleukin-12 and the regulation of innate resistance and adaptive immunity.

Authors:  Giorgio Trinchieri
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

10.  Interleukin 12 p40 production by barrier epithelial cells during airway inflammation.

Authors:  M J Walter; N Kajiwara; P Karanja; M Castro; M J Holtzman
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

View more
  8 in total

1.  Detection of respiratory viruses and the associated chemokine responses in serious acute respiratory illness.

Authors:  Kaharu C Sumino; Michael J Walter; Cassandra L Mikols; Samantha A Thompson; Monique Gaudreault-Keener; Max Q Arens; Eugene Agapov; David Hormozdi; Anne M Gaynor; Michael J Holtzman; Gregory A Storch
Journal:  Thorax       Date:  2010-07       Impact factor: 9.139

2.  Alveolar macrophages contribute to the pathogenesis of human metapneumovirus infection while protecting against respiratory syncytial virus infection.

Authors:  Deepthi Kolli; Meera R Gupta; Elena Sbrana; Thangam S Velayutham; Hong Chao; Antonella Casola; Roberto P Garofalo
Journal:  Am J Respir Cell Mol Biol       Date:  2014-10       Impact factor: 6.914

3.  Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics.

Authors:  Yongjian Liu; Aida Ibricevic; Joel A Cohen; Jessica L Cohen; Sean P Gunsten; Jean M J Fréchet; Michael J Walter; Michael J Welch; Steven L Brody
Journal:  Mol Pharm       Date:  2009 Nov-Dec       Impact factor: 4.939

4.  Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis.

Authors:  Avraham Beigelman; Cassandra L Mikols; Sean P Gunsten; Carolyn L Cannon; Steven L Brody; Michael J Walter
Journal:  Respir Res       Date:  2010-06-30

5.  Genetic contribution of CISH promoter polymorphisms to susceptibility to tuberculosis in Chinese children.

Authors:  Lin Sun; Ya-qiong Jin; Chen Shen; Hui Qi; Ping Chu; Qing-qin Yin; Jie-qiong Li; Jian-ling Tian; Wei-wei Jiao; Jing Xiao; A-dong Shen
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

6.  PEGylation of cationic, shell-crosslinked-knedel-like nanoparticles modulates inflammation and enhances cellular uptake in the lung.

Authors:  Aida Ibricevic; Sean P Guntsen; Ke Zhang; Ritu Shrestha; Yongjian Liu; Jing Yi Sun; Michael J Welch; Karen L Wooley; Steven L Brody
Journal:  Nanomedicine       Date:  2013-02-27       Impact factor: 5.307

7.  Increased production of IL-4 and IL-12p40 from bronchoalveolar lavage cells are biomarkers of Mycobacterium tuberculosis in the sputum.

Authors:  Anna Nolan; Elaine Fajardo; Maryann L Huie; Rany Condos; Anil Pooran; Rodney Dawson; Keertan Dheda; Eric Bateman; William N Rom; Michael D Weiden
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

8.  Synthesis, characterization, and in vivo efficacy of shell cross-linked nanoparticle formulations carrying silver antimicrobials as aerosolized therapeutics.

Authors:  Parth N Shah; Lily Yun Lin; Justin A Smolen; Jasur A Tagaev; Sean P Gunsten; Daniel S Han; Gyu Seong Heo; Yali Li; Fuwu Zhang; Shiyi Zhang; Brian D Wright; Matthew J Panzner; Wiley J Youngs; Steven L Brody; Karen L Wooley; Carolyn L Cannon
Journal:  ACS Nano       Date:  2013-06-04       Impact factor: 15.881

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.